Tonix posts $15 million in TONMYA sales for Q3, cites pipeline progress

Tonix Pharmaceuticals Holding Corp. reported financial results and operational highlights for the quarter ended September 30, 2026, on November 9, 2026. The company said third quarter TONMYA net sales were approximately $15 million, up 37% from the second quarter¹.

On the pipeline side, Tonix said enrollment is continuing in a study called "HORIZON," described as a potentially pivotal, six-week, randomized, double-blind, placebo-controlled Phase 2 trial testing TNX-102 SL at 5.6 mg as a first-line monotherapy in adults with major depressive disorder¹. For TNX-4800, its Lyme disease prevention antibody, the company said it received positive official minutes from a Type C meeting with the FDA on August 3, 2026, and that the FDA is reviewing the final study protocol¹. Tonix added that the adaptive Phase 2 TRAIL field study is expected to begin in the first quarter of 2027 pending final FDA agreement on the protocol, and that it is on track to deliver investigational product to study sites in that same quarter¹. For TNX-1500 (mosdaprubart), an investigator-initiated kidney transplant study at Massachusetts General Hospital, the company said the Phase 2, open-label trial is expected to begin in the first quarter of 2027 and enroll five adult kidney transplant recipients¹.

On commercial execution, Tonix noted total prescriptions rose, including bridge prescriptions through its digital pharmacy channel, which the company described as initial fills issued while coverage decisions are pending that do not generate immediate net revenue¹.

On finances, Tonix said it had approximately $163 million in cash and cash equivalents as of September 30, 2026, compared to approximately $207.6 million as of December 31, 2025¹. The company said it believes its cash position as of September 30, 2026, together with about $1.5 million raised from later equity offerings, will fund operations into the early third quarter of 2027¹.